Disruptive Science
Driven by Heart

Our mission is to develop novel therapeutics, bridging the innovation gap for patients in China and the world.

vline-orange
Ji Xing completes Phase 1 study of aficamten, a potential next-generation cardiac myosin inhibitor, for patients with hypertrophic cardiomyopathy (HCM)
vline-orange
JIXING Announces IND Approval for Phase 1 and Phase 3 Clinical Trials of Etripamil in Patients with Paroxysmal Supraventricular Tachycardia (PSVT) in China
vline-orange
Chinese startup with Merck vet at the helm acquires rights to Oyster Point’s eye disease nasal spray

JIXING is a leading biotechnology company committed to bringing innovative science and medicines to underserved patients in China

China Biotech

A differentiated China-based biotech with a patient-centric approach dedicated to improving outcomes in Cardiovascular and Ophthalmology.
Learn more

Strong Pipeline

A growing pipeline of high-quality, de-risked assets based on clinical results of our partners and with significant market potential in Greater China.
Learn more

World-class Team

A world-class team with strong clinical execution and regulatory experience, led by a CEO with substantial commercial experience in Greater China.
Learn more

Strategic Partners

Founded and backed by RTW Investments, a leading global, full life-cycle healthcare investment firm and a proven company builder.
Learn more

Room 2801, Level 28, Tower 2 Plaza 66,
1266 West Nanjing Road,
Jing’an District, Shanghai 200040

+86-021-80311808

Copyright © 2021 JIXING Pharmaceuticals.
All Rights Reserved.
Privacy Notice | Terms of Use
Pipeline & Science
Our Expertise
Scroll to Top